Immunotherapy has been applied to triple negative breast cancers (TNBCs) (8) as well, but the efficacy of immunotherapy for HER2+ breast cancers remains unclear and requires further investigation. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.